| Name | Title | Contact Details |
|---|
Cedarburg Pharmaceuticals delivers unsurpassed value in the development and manufacturing of commercial and clinical APIs. We believe value is more than just price. Value means making your life simpler. Our process development, scale-up, commercial
Aurora Cannabis Inc. is a world-renowned integrated cannabis company with an industry-leading reputation for continuously elevating and setting the global cannabis industry standard. Through our wholly owned subsidiaries, strategic investments, and global partnerships, Aurora provides a wide range of premium quality cannabis and hemp products and services, develops innovative technologies, promotes cannabis consumer health and wellness, and delivers an exceptional customer experience across all its brands. Aurora`s operations span multiple continents and focuses on both the medical and recreational cannabis production and sales, patient education and clinic counselling services, home hydroponic cultivation, extraction technologies and delivery systems, and hemp-based food health products. We operate around the globe pursuing new and emerging cannabis markets where possible through our owned network of import, export and wholesale distributors, and our e-commerce and mobile applications.
Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.
Leader in the manufacture of generic drugs, we produce and distribute brand name drugs and over-the-counter drugs. Based in Montreal, Canada, we have about 1 500 employees. Our products are sold in more than sixty countries. Our portfolio of 340 products cumulates 2000 different dosage strengths. We invest $ 30 million per year in research and development. We firmly believe that we must be an example in our community. We support many charities, here as elsewhere. For international humanitarian purposes, we have donated products valued at approximately $ 23.5 million over the past five years.